John H. Healey, MD, FACS
Chief, Orthopedic Surgery
Memorial Sloan Kettering Cancer Center
New York, NY
This enduring activity is focused on the management of patients with Tenosynovial Giant Cell Tumor (TGCT)
This CME initiative is designed to meet the educational needs of US-based orthopedic surgeons, sarcoma specialists, oncologic surgeons, medical oncologists, and other primary healthcare professionals (physicians, physician assistants, nurse practitioners) involved in the management of patients with TGCT.
After completing the CME activity, learners should be better able to:
- Discuss challenges and unmet needs associated with traditional standard of care therapies for the management of TGCT
- Review the role of the CSF1 pathway in the pathogenesis of tumor growth in patients with TGCT
- Describe the MOAs and clinical trial profiles of CSF1 receptor inhibitors for the treatment of TGCT
- Explain the benefits of professionals working across specialties to manage some recurrent, diffuse, or difficult-to-treat cases of TGCT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 1.25 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with TGCT.
CNE Credits: 1.25 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
John H. Healey, MD, has disclosed that he is a consultant for Daiichi Sankyo, Inc.
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Melissa A Johnson, Sr. Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the activity; and
3. Complete pre-and-post surveys and evaluation.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: February 21, 2020
EXPIRATION DATE: February 21, 2021
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.